JP7443255B2 - 疼痛使用のためのｃｈ２４ｈ阻害剤 - Google Patents

疼痛使用のためのｃｈ２４ｈ阻害剤 Download PDF

Info

Publication number
JP7443255B2
JP7443255B2 JP2020567621A JP2020567621A JP7443255B2 JP 7443255 B2 JP7443255 B2 JP 7443255B2 JP 2020567621 A JP2020567621 A JP 2020567621A JP 2020567621 A JP2020567621 A JP 2020567621A JP 7443255 B2 JP7443255 B2 JP 7443255B2
Authority
JP
Japan
Prior art keywords
pain
cancer
composition
dose
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500351A5 (https=
JPWO2020059894A5 (https=
JP2022500351A (ja
Inventor
アスガルネハド、マナズ
アルキロ、ディミトリオス
俊哉 西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022500351A publication Critical patent/JP2022500351A/ja
Publication of JP2022500351A5 publication Critical patent/JP2022500351A5/ja
Publication of JPWO2020059894A5 publication Critical patent/JPWO2020059894A5/ja
Application granted granted Critical
Publication of JP7443255B2 publication Critical patent/JP7443255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020567621A 2018-09-20 2019-09-19 疼痛使用のためのｃｈ２４ｈ阻害剤 Active JP7443255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733927P 2018-09-20 2018-09-20
US62/733,927 2018-09-20
PCT/JP2019/038061 WO2020059894A1 (en) 2018-09-20 2019-09-19 CH24H Inhibitors For Pain Use

Publications (4)

Publication Number Publication Date
JP2022500351A JP2022500351A (ja) 2022-01-04
JP2022500351A5 JP2022500351A5 (https=) 2022-09-20
JPWO2020059894A5 JPWO2020059894A5 (https=) 2022-09-20
JP7443255B2 true JP7443255B2 (ja) 2024-03-05

Family

ID=68343384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567621A Active JP7443255B2 (ja) 2018-09-20 2019-09-19 疼痛使用のためのｃｈ２４ｈ阻害剤

Country Status (4)

Country Link
US (1) US20210346366A1 (https=)
EP (1) EP3852757A1 (https=)
JP (1) JP7443255B2 (https=)
WO (1) WO2020059894A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054822A1 (en) 2011-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
JP2015501302A (ja) 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP2017520540A (ja) 2014-06-09 2017-07-27 武田薬品工業株式会社 放射標識された化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151162A1 (es) 2012-12-11 2015-08-28 Takeda Pharmaceutical Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h)
CN105164161A (zh) * 2013-03-13 2015-12-16 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP6272832B2 (ja) * 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054822A1 (en) 2011-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
JP2015501302A (ja) 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP2017520540A (ja) 2014-06-09 2017-07-27 武田薬品工業株式会社 放射標識された化合物

Also Published As

Publication number Publication date
WO2020059894A1 (en) 2020-03-26
US20210346366A1 (en) 2021-11-11
JP2022500351A (ja) 2022-01-04
EP3852757A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
JP7525903B2 (ja) Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
AU2020239656B2 (en) Autotaxin inhibitors and uses thereof
RS60731B1 (sr) Čvrsti oblici jedinjenja koje modulira kinaze
US20110086868A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
CN113018300A (zh) 用于治疗神经病症的方法
WO2019173482A1 (en) 4-aminoquinoline compounds for the treatment of angiogenesis
WO2021064141A1 (en) Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
CN105748465A (zh) 用于治疗癌症的多激酶抑制剂
JP7443255B2 (ja) 疼痛使用のためのｃｈ２４ｈ阻害剤
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
CA3212085C (en) HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
AU2017316756A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
WO2022261643A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
WO2018009694A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
JP2018123108A (ja) 三環性スピロ化合物の安定結晶
JP7200453B2 (ja) Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体
JP2017114764A (ja) 片頭痛治療剤
WO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
TWI913256B (zh) 作為ＨＥＲ２抑制劑之[１,３]二基[５,４-ｄ]嘧啶
CN121941686A (zh) 用于治疗神经退行性疾病的融合杂环
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40077153A (en) Autotaxin inhibitors and uses thereof
EA048371B1 (ru) Гетероциклические производные, фармацевтические композиции и их применение при лечении рака или для улучшения состояния при раке
EA043296B1 (ru) Производные пиридопиримидинона для применения в качестве ингибиторов axl

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240221

R150 Certificate of patent or registration of utility model

Ref document number: 7443255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150